NPPA has put a cap on Trade Margin of 42 select non-scheduled anti-cancer medicines under ‘Trade Margin Rationalization (TMR)’ Approach resulting in reduction up to 90% of Maximum Retail Price (MRP) of 526 brands of these medicines.
National Pharmaceuticals Pricing Policy (NPPP), 2012 prescribes the guidelines for regulation of prices of drugs. The key principles of price regulation are (i) essentiality of drugs (ii) control of prices of formulations and (iii) MarketBased Pricing. Based on NPPP, 2012 and subsequent Drugs (Prices Control) Order, 2013 (DPCO, 2013), National Pharmaceutical Pricing Authority (NPPA) under […]
Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Pivotal phase III POLARIX trial comparing Polivy in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first-line diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of investigator-assessed progression-free survival Prolonging survival without disease advancement could be transformative for newly diagnosed DLBCL patients as currently 40% of patients relapse […]
Fraudulent “COVID-19 Compensation Lottery Prize” scam, falsely alleges association with WHO and othersWHO Warns of Fraudulent COVID-19 Compensation Lottery Scam
Geneva--6 August 2021--The World Health Organization (WHO) has been made aware of correspondences being circulated by scammers (acting under the name of Capital Finance, Inc. London), falsely notifying recipients of such correspondences that they have been selected as a beneficiary/winner of a US$1 million lottery compensation prize payment for losses and damages suffered as a […]
Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Pivotal phase III POLARIX trial comparing Polivy in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first-line diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of investigator-assessed progression-free survival Prolonging survival without disease advancement could be transformative for newly diagnosed DLBCL patients as currently 40% of patients relapse […]
Foreign nationals are now eligible for Vaccination in India
In a landmark initiative to ensure safety from COVID-19, Ministry of Health and Family Welfare has taken a decision to allow foreign nationals residing in India to get registered on CoWin portal to take COVID-19 vaccine. They can use their passport as identity document for the purpose of registration on CoWIN portal. Once they are […]
Health Ministry’s eSanjeevani completes 90 Lakh consultations
The National Telemedicine Service of the Ministry of Health & Family Welfare has completed 90 lakh teleconsultations in the country. The last 10 lakh consultations came up in record 17 days. Government of India’s eSanjeevani initiative has gained popularity amongst doctors and patients across country. New users are continuously adopting telemedicine as eSanjeevani has proved […]
Hon’ble Vice President Shri Venkaiah Naidu and Speaker, Lok Sabha Shri Om Birla chair event to sensitise Parliamentarians on India’s efforts to eliminate TB
Vice President of India and Chairman of Rajya Sabha Shri Venkaiah Naidu along with Speaker of Lok Sabha Shri Om Birla chaired an event today to sensitise Parliamentarians on the country’s efforts to eliminate TB. Shri Mansukh Mandaviya, Union Minister for Health and Family Welfare and Dr. Bharati Pravin Pawar, Union Minister of State for […]
Ongoing Initiatives to Strengthen Healthcare Infrastructure
Government of India has provided the required technical support and has also supported the states through logistic and financial support to further strengthen the existing health infrastructure to tackle COVID-19 pandemic. Some of the ongoing initiatives to further strengthen healthcare infrastructure include: With the intent to reduce the risk of cross infection to non-COVID patients […]
Facility augmentation of Bharat Biotech and 3 other PSEs are being supported, for augmented production of Covaxin
The manufacturing cost of medicine/vaccine is dependent of factors such as development cost, Intellectual Property Rights (IPR) cost, technology, vaccine platform & scale of production in different companies. Department of Biotechnology has informed that under “Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission”, being implemented by Biotechnology Industry Research Assistance Council (BIRAC), a Public […]
Asthma Patients
A study ‘The burden of chronic respiratory diseases and their heterogeneity across the states of India: The Global Burden of Disease Study 1990-2016” was published in Lancet 2018 by ICMR. As per the study, the prevalence of Asthma reduced from 3468 per 100000 in 1990 to 3336 per 100000 in 2016 showing a decline of […]
